CO2023001795A2 - Agonistas de bicicloheptano pirrolidina de los receptores de orexina - Google Patents
Agonistas de bicicloheptano pirrolidina de los receptores de orexinaInfo
- Publication number
- CO2023001795A2 CO2023001795A2 CONC2023/0001795A CO2023001795A CO2023001795A2 CO 2023001795 A2 CO2023001795 A2 CO 2023001795A2 CO 2023001795 A CO2023001795 A CO 2023001795A CO 2023001795 A2 CO2023001795 A2 CO 2023001795A2
- Authority
- CO
- Colombia
- Prior art keywords
- orexin receptors
- agonists
- pyrrolidine
- bicycloheptane
- relates
- Prior art date
Links
- 108050000742 Orexin Receptor Proteins 0.000 title abstract 4
- 102000008834 Orexin receptor Human genes 0.000 title abstract 4
- 239000000556 agonist Substances 0.000 title abstract 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 3
- ARUKYTASOALXFG-UHFFFAOYSA-N cycloheptylcycloheptane Chemical compound C1CCCCCC1C1CCCCCC1 ARUKYTASOALXFG-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- -1 bicyclo[4.1.0]heptane pyrrolidine compounds Chemical class 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Abstract
La presente invención se refiere a compuestos de biciclo[4.1.0]heptano pirrolidina que son agonistas de los receptores de orexina. La presente invención también se refiere a usos de los compuestos descritos en el presente documento en el tratamiento o prevención potencial de trastornos y enfermedades neurológicas y psiquiátricas en las que están involucrados los receptores de orexina. La presente invención también se refiere a composiciones que comprenden estos compuestos. La presente invención también se refiere a usos de estas composiciones en la prevención o tratamiento potencial de dichas enfermedades en las que están involucrados los receptores de orexina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063066908P | 2020-08-18 | 2020-08-18 | |
US202163226798P | 2021-07-29 | 2021-07-29 | |
PCT/US2021/046098 WO2022040070A1 (en) | 2020-08-18 | 2021-08-16 | Bicycloheptane pyrrolidine orexin receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2023001795A2 true CO2023001795A2 (es) | 2023-03-17 |
Family
ID=77655694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2023/0001795A CO2023001795A2 (es) | 2020-08-18 | 2023-02-17 | Agonistas de bicicloheptano pirrolidina de los receptores de orexina |
Country Status (18)
Country | Link |
---|---|
US (2) | US11680060B2 (es) |
EP (1) | EP4200295A1 (es) |
JP (1) | JP7443625B2 (es) |
KR (1) | KR20230053639A (es) |
CN (1) | CN116249697A (es) |
AU (1) | AU2021329805B2 (es) |
BR (1) | BR112023002957A2 (es) |
CA (1) | CA3189908A1 (es) |
CL (1) | CL2023000468A1 (es) |
CO (1) | CO2023001795A2 (es) |
CR (1) | CR20230089A (es) |
DO (1) | DOP2023000036A (es) |
EC (1) | ECSP23012026A (es) |
IL (1) | IL300610A (es) |
MX (1) | MX2023001840A (es) |
PE (1) | PE20231384A1 (es) |
TW (1) | TW202227417A (es) |
WO (1) | WO2022040070A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL293240A (en) | 2019-11-25 | 2022-07-01 | Alkermes Inc | Transmutable macrocyclic compounds, preparations containing them and their uses |
US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
Family Cites Families (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2263702A (en) | 1939-01-18 | 1941-11-25 | Konstruktion Und Verwertung Au | Centrifugal clutch construction |
US3914250A (en) | 1974-08-01 | 1975-10-21 | American Home Prod | 1,4-Diazepino{8 6,5,4-jk{9 carbazoles |
US4919602A (en) | 1987-12-21 | 1990-04-24 | Janszen Arthur W | Apparatus for repairing windshields |
MX18467A (es) | 1988-11-23 | 1993-07-01 | Pfizer | Agentes terapeuticos de quinuclidinas |
US5232929A (en) | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
US5081122A (en) | 1990-03-05 | 1992-01-14 | Sterling Drug Inc. | Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof |
US5112820A (en) | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
US5013837A (en) | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
US4973587A (en) | 1990-03-08 | 1990-11-27 | Sterling Drug Inc. | 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method |
DE69220258T2 (de) | 1991-02-11 | 1997-12-18 | Merck Sharp & Dohme | Azabicyclische Verbindungen, diese enthaltende pharmazeutische Zubereitungen und ihre therapeutische Verwendung |
ES2065175T3 (es) | 1991-03-01 | 1995-02-01 | Pfizer | Derivados de 1-azabiciclo(3.2.2)nonan-3-amina. |
EP0600952B1 (en) | 1991-08-20 | 1996-04-17 | MERCK SHARP & DOHME LTD. | Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
GB9211193D0 (en) | 1992-05-27 | 1992-07-08 | Merck Sharp & Dohme | Therapeutic agents |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
US5637699A (en) | 1992-06-29 | 1997-06-10 | Merck & Co., Inc. | Process for preparing morpholine tachykinin receptor antagonists |
US5387595A (en) | 1992-08-26 | 1995-02-07 | Merck & Co., Inc. | Alicyclic compounds as tachykinin receptor antagonists |
US5578593A (en) | 1992-12-11 | 1996-11-26 | Merck & Co., Inc. | Spiro piperidines and homologs promote release of growth hormone |
US5292736A (en) | 1993-02-26 | 1994-03-08 | Sterling Winthrop Inc. | Morpholinoalkylindenes as antiglaucoma agents |
US5496833A (en) | 1993-04-13 | 1996-03-05 | Merck Sharp & Dohme Limited | Piperidine tachykinin receptor antagonists |
BR9509610A (pt) | 1994-11-07 | 1997-10-28 | Pfizer | Ligandos específicos de neuropeptideo Y1 |
US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
US5831115A (en) | 1995-04-21 | 1998-11-03 | Abbott Laboratories | Inhibitors of squalene synthase and protein farnesyltransferase |
US5739106A (en) | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
AU7626496A (en) | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Heteroaryl compounds |
WO1997020823A2 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | 2-amino quinazoline derivatives as npy receptor antagonists |
WO1997020821A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl derivatives |
WO1997019682A1 (en) | 1995-12-01 | 1997-06-05 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
AU7692896A (en) | 1995-12-01 | 1997-06-27 | Novartis Ag | Quinazolin-2,4-diazirines as NPY receptor antagonist |
AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
KR19990082330A (ko) | 1996-02-06 | 1999-11-25 | 미즈노 마사루 | 신규 화합물 및 이의 의약 용도 |
GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
EP0955293B1 (en) | 1996-12-03 | 2003-03-19 | Banyu Pharmaceutical Co., Ltd. | Urea derivatives |
WO1998025907A1 (fr) | 1996-12-12 | 1998-06-18 | Banyu Pharmaceutical Co., Ltd. | Derives de pyrazole |
US6166038A (en) | 1996-12-13 | 2000-12-26 | Banyu Pharmaceutical Co., Ltd. | Aminopyrazole derivatives |
CA2274594C (en) | 1996-12-16 | 2006-10-10 | Banyu Pharmaceutical Co., Ltd. | Aminopyrazole derivatives |
EP0971588B1 (en) | 1997-01-21 | 2004-03-17 | Smithkline Beecham Corporation | Novel cannabinoid receptor modulators |
CN1982290A (zh) | 1997-02-04 | 2007-06-20 | 阿肯色大学评议会 | 杀菌的羧酰胺 |
DK0966436T3 (da) | 1997-02-21 | 2003-03-31 | Bayer Ag | Arylsulfonamider og analoger deraf og anvendelse deraf til behandling af neurodegenerative lidelser |
WO1998040356A1 (fr) | 1997-03-12 | 1998-09-17 | Banyu Pharmaceutical Co., Ltd. | Medicaments contenant des derives d'aminopyridine comme ingredient actif |
WO1998041519A1 (en) | 1997-03-18 | 1998-09-24 | Smithkline Beecham Corporation | Novel cannabinoid receptor agonists |
FR2761265B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates |
FR2761266B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
CA2288122C (en) | 1997-04-23 | 2006-09-26 | Banyu Pharmaceutical Co., Ltd. | Neuropeptide y receptor antagonist |
US6001836A (en) | 1997-05-28 | 1999-12-14 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: cyanoguanidine derivatives |
KR20010021696A (ko) | 1997-07-11 | 2001-03-15 | 미즈노 마사루 | 퀴놀린 화합물 및 그의 의약용도 |
WO1999015516A1 (fr) | 1997-09-25 | 1999-04-01 | Banyu Pharmaceutical Co., Ltd. | Nouveaux antagonistes des recepteurs de neuropeptides y |
AU1262199A (en) | 1997-11-28 | 1999-06-16 | Banyu Pharmaceutical Co., Ltd. | Antihyperlipemic agents |
AU3464599A (en) | 1998-04-02 | 1999-10-25 | Neurogen Corporation | Aminoalkyl substituted 9h-pyridino(2,3-b)indole and 9h-pyrimidino(4,5-b)indole derivatives |
JP2004503462A (ja) | 1998-04-29 | 2004-02-05 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 肥満症及び他の障害の処置において有用な神経ペプチドyy5レセプターのためのリガンドとしてのn−置換アミノテトラリン |
US6329395B1 (en) | 1998-06-08 | 2001-12-11 | Schering Corporation | Neuropeptide Y5 receptor antagonists |
DE19837627A1 (de) | 1998-08-19 | 2000-02-24 | Bayer Ag | Neue Aminosäureester von Arylsulfonamiden und Analoga |
HN1998000027A (es) | 1998-08-19 | 1999-06-02 | Bayer Ip Gmbh | Arilsulfonamidas y analagos |
US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
US6337332B1 (en) | 1998-09-17 | 2002-01-08 | Pfizer Inc. | Neuropeptide Y receptor antagonists |
DE69929235T2 (de) | 1998-11-10 | 2006-08-24 | Merck & Co., Inc. | Spiro-indole als y5-rezeptor antagonisten |
DK1183245T3 (da) | 1999-04-22 | 2007-09-24 | Lundbeck & Co As H | Selektive NPY(Y5)-antagonister |
US6340683B1 (en) | 1999-04-22 | 2002-01-22 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (triazines) |
MXPA01011321A (es) | 1999-05-05 | 2003-08-01 | Johnson & Johnson | Neuropeptidos y ligandos de receptores 3a, 4, 5, 9b-tetrahidro-1h-benz(e)indol-2-il amino derivados utiles en el tratamiento de obesidad y otros trastornos. |
DE60023128T2 (de) | 1999-05-12 | 2006-07-06 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazolcarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen |
CA2380866A1 (en) | 1999-06-30 | 2001-01-11 | Synaptic Pharmaceutical Corporation | Selective npy (y5) antagonists |
WO2001007409A1 (en) | 1999-07-23 | 2001-02-01 | Astrazeneca Uk Limited | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
US6380224B1 (en) | 1999-07-28 | 2002-04-30 | Ortho-Mcneil Pharmaceutical, Inc. | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders |
TWI279402B (en) | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
US6462053B1 (en) | 1999-08-20 | 2002-10-08 | Banyu Pharmaceutical Co., Ltd. | Spiro compounds |
EP1219294A4 (en) | 1999-09-20 | 2005-01-26 | ANTAGONISTS OF THE MELANIN CONCENTRATING HORMON | |
WO2001021577A2 (en) | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
CZ20021089A3 (cs) | 1999-09-30 | 2002-11-13 | Neurogen Corporation | Aminosustituované pyrazolo[1,5-a]-1,5-pyrimidiny a pyrazolo[1,5-a]-1,3,5-triaziny |
EA200200424A1 (ru) | 1999-09-30 | 2002-12-26 | Ньюроджен Корпорейшн | Некоторые гетероциклы, замещенные алкилендиамином |
HUP0202678A3 (en) | 1999-09-30 | 2004-06-28 | Pfizer | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines, pharmaceutical compositions containing them and their use |
US6444687B1 (en) | 1999-12-16 | 2002-09-03 | Schering Corporation | Substituted imidazole neuropeptide Y Y5 receptor antagonists |
AU2001228325A1 (en) | 2000-02-01 | 2001-08-14 | Novo-Nordisk A/S | Use of compounds for the regulation of food intake |
JP2004502642A (ja) | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
AU2001234128B2 (en) | 2000-02-22 | 2004-11-11 | Banyu Pharmaceutical Co., Ltd. | Novel imidazoline compounds |
US6531478B2 (en) | 2000-02-24 | 2003-03-11 | Cheryl P. Kordik | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
FR2805817B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
FR2805818B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
FR2805810B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
EP1132389A1 (en) | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | New aza-indolyl derivatives for the treatment of obesity |
EP1142886A1 (en) | 2000-04-07 | 2001-10-10 | Aventis Pharma Deutschland GmbH | Percyquinnin, a process for its production and its use as a pharmaceutical |
WO2001082925A1 (fr) | 2000-04-28 | 2001-11-08 | Takeda Chemical Industries, Ltd. | Antagonistes de l'hormone concentrant la melanine |
GB0010757D0 (en) | 2000-05-05 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
GB0011013D0 (en) | 2000-05-09 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
US6432960B2 (en) | 2000-05-10 | 2002-08-13 | Bristol-Myers Squibb Company | Squarate derivatives of dihydropyridine NPY antagonists |
AU2001263021A1 (en) | 2000-05-10 | 2001-11-20 | Bristol-Myers Squibb Company | Alkylamine derivatives of dihydropyridine npy antagonists |
US6444675B2 (en) | 2000-05-10 | 2002-09-03 | Bristol-Myers Squibb Company | 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists |
US7229986B2 (en) | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
AU2001259056A1 (en) | 2000-05-17 | 2001-11-26 | Eli Lilly And Company | Method for selectively inhibiting ghrelin action |
US6391881B2 (en) | 2000-05-19 | 2002-05-21 | Bristol-Myers Squibb Company | Thiourea derivatives of dihydropyridine NPY antagonists |
SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
AU783403B2 (en) | 2000-07-05 | 2005-10-20 | H. Lundbeck A/S | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
JP2004516239A (ja) | 2000-07-06 | 2004-06-03 | ニューロジェン コーポレイション | メラニン凝集ホルモン受容体リガンド |
AU2001283938A1 (en) | 2000-07-24 | 2002-02-05 | Ardana Bioscience Limited | Ghrelin antagonists |
AU2001283955B2 (en) | 2000-07-31 | 2006-05-18 | F. Hoffmann-La Roche Ag | Piperazine derivatives |
JP2004509108A (ja) | 2000-09-14 | 2004-03-25 | シェーリング コーポレイション | 置換尿素神経ペプチドyy5受容体アンタゴニスト |
JP2004511552A (ja) | 2000-10-13 | 2004-04-15 | イーライ・リリー・アンド・カンパニー | 成長ホルモン分泌促進薬としての置換ジペプチド |
CN100334076C (zh) | 2000-10-16 | 2007-08-29 | 霍夫曼-拉罗奇有限公司 | 二氢吲哚衍生物及其作为5-ht2受体配体的用途 |
AU2002227170A1 (en) | 2000-11-03 | 2002-05-15 | Wyeth | Cycloalkyl(b)(1,4)diazepino(6,7,1-hi)indoles and derivatives |
NZ525700A (en) | 2000-11-20 | 2004-12-24 | Biovitrum Ab | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor |
PL360982A1 (en) | 2000-11-20 | 2004-09-20 | Biovitrum Ab | Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor |
MXPA03004245A (es) | 2000-12-12 | 2003-09-22 | Neurogen Corp | Espiro[isobenzofuran-1,4'piperidin]-3-onas y 3h-espiroisobenzofuran-1,4'-piperidinas. |
GB0030710D0 (en) | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
IL156157A0 (en) | 2000-12-21 | 2003-12-23 | Schering Corp | Heteroaryl urea neuropeptide y y5 receptor antagonists |
ES2243588T3 (es) | 2000-12-22 | 2005-12-01 | Schering Corporation | Antagonistas piperidinicos de la mch y su uso en el tratamientyo de la obesidad. |
CA2432085C (en) | 2000-12-27 | 2009-02-24 | F. Hoffmann-La Roche Ag | Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands |
PL364221A1 (en) | 2001-02-02 | 2004-12-13 | Takeda Chemical Industries, Ltd. | Fused heterocyclic compounds |
US6900329B2 (en) | 2001-03-21 | 2005-05-31 | Schering Corporation | MCH antagonists and their use in the treatment of obesity |
CN100537527C (zh) | 2001-03-21 | 2009-09-09 | 法马科皮亚公司 | 具有mch调节活性的芳基和二芳基化合物 |
RU2281941C2 (ru) | 2001-03-22 | 2006-08-20 | Солвей Фармасьютикалс Б.В. | Производные 4,5-дигидро-1h-пиразола, обладающие cb1-антагонистической активностью |
US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
JP4280073B2 (ja) | 2001-04-12 | 2009-06-17 | ファーマコペイア ドラッグ ディスカバリー, インコーポレイテッド | Mchアンタゴニストとして使用されるアリールピペリジンおよびビアリールピペリジン |
FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
MXPA03010612A (es) | 2001-05-22 | 2004-04-02 | Neurogen Corp | Ligandos receptores de la hormona concentradora de melanina: analogos de 1-bencil-4-aril piperazina substiruidos. |
WO2002094825A1 (fr) | 2001-05-22 | 2002-11-28 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de spiropiperidine |
JP2005500308A (ja) | 2001-06-20 | 2005-01-06 | メルク エンド カムパニー インコーポレーテッド | 糖尿病を治療するためのジペプチジルペプチダーゼ阻害剤 |
CA2450579A1 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
CA2419888A1 (en) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
IL158923A0 (en) | 2001-06-27 | 2004-05-12 | Smithkline Beecham Corp | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
JP4300108B2 (ja) | 2001-06-27 | 2009-07-22 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのピロリジン類 |
ATE370943T1 (de) | 2001-06-27 | 2007-09-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
EP1404675B1 (en) | 2001-07-03 | 2008-03-12 | Novo Nordisk A/S | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
HUP0401880A2 (hu) | 2001-07-05 | 2005-01-28 | Synaptic Pharmaceutical Corporation | Helyettesített anilin-piperidinek mint MCH-szelektív antagonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
AU2002319627A1 (en) | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
BRPI0104510B8 (pt) | 2001-07-27 | 2021-05-25 | Embrapa Pesquisa Agropecuaria | peptídeos antibióticos da família das phylloseptinas isolados da secreção da pele de phylloseptina hypocondrialis e composição antimicrobiana relacionada |
CN1538956A (zh) | 2001-08-07 | 2004-10-20 | ������ҩ��ʽ���� | 螺环化合物 |
JP2005320249A (ja) | 2002-05-01 | 2005-11-17 | Banyu Pharmaceut Co Ltd | 2−アミノピラジン誘導体の製造方法 |
AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
US6869966B2 (en) | 2002-09-30 | 2005-03-22 | Banyu Pharmaceutical Co., Ltd. | N-substituted-2-oxodihydropyridine derivatives |
MY134457A (en) | 2002-11-22 | 2007-12-31 | Merck & Co Inc | Substituted amides |
JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
RU2006100298A (ru) | 2003-06-11 | 2006-05-10 | Мерк энд Ко., Инк. (US) | Замещенные производные 3-алкил-и 3-алкенилазетидинов |
EP2694472B1 (en) | 2011-04-05 | 2020-03-11 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
PL3411358T3 (pl) | 2016-02-04 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Podstawiony związek piperydynowy i jego zastosowanie |
WO2018164192A1 (ja) | 2017-03-08 | 2018-09-13 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
US11059780B2 (en) | 2017-03-08 | 2021-07-13 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
CN111051295B (zh) | 2017-08-03 | 2022-09-02 | 武田药品工业株式会社 | 杂环化合物及其用途 |
EP3663281B1 (en) * | 2017-08-03 | 2022-12-28 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
JP7413261B2 (ja) | 2018-06-29 | 2024-01-15 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
WO2020004536A1 (ja) | 2018-06-29 | 2020-01-02 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
JP7408569B2 (ja) | 2018-12-12 | 2024-01-05 | 武田薬品工業株式会社 | 複素環化合物 |
US20230042358A1 (en) | 2018-12-12 | 2023-02-09 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
CA3124536A1 (en) | 2019-01-31 | 2020-08-06 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
US11098029B2 (en) * | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
-
2021
- 2021-08-16 AU AU2021329805A patent/AU2021329805B2/en active Active
- 2021-08-16 BR BR112023002957A patent/BR112023002957A2/pt unknown
- 2021-08-16 KR KR1020237008981A patent/KR20230053639A/ko unknown
- 2021-08-16 MX MX2023001840A patent/MX2023001840A/es unknown
- 2021-08-16 TW TW110130112A patent/TW202227417A/zh unknown
- 2021-08-16 WO PCT/US2021/046098 patent/WO2022040070A1/en active Application Filing
- 2021-08-16 US US17/402,932 patent/US11680060B2/en active Active
- 2021-08-16 IL IL300610A patent/IL300610A/en unknown
- 2021-08-16 PE PE2023000316A patent/PE20231384A1/es unknown
- 2021-08-16 EP EP21766336.8A patent/EP4200295A1/en active Pending
- 2021-08-16 CR CR20230089A patent/CR20230089A/es unknown
- 2021-08-16 CN CN202180067840.8A patent/CN116249697A/zh active Pending
- 2021-08-16 CA CA3189908A patent/CA3189908A1/en active Pending
- 2021-08-16 JP JP2023511949A patent/JP7443625B2/ja active Active
- 2021-08-16 US US18/040,896 patent/US20230365533A1/en active Pending
-
2023
- 2023-02-15 CL CL2023000468A patent/CL2023000468A1/es unknown
- 2023-02-16 EC ECSENADI202312026A patent/ECSP23012026A/es unknown
- 2023-02-17 CO CONC2023/0001795A patent/CO2023001795A2/es unknown
- 2023-02-17 DO DO2023000036A patent/DOP2023000036A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4200295A1 (en) | 2023-06-28 |
JP2023533604A (ja) | 2023-08-03 |
TW202227417A (zh) | 2022-07-16 |
WO2022040070A1 (en) | 2022-02-24 |
PE20231384A1 (es) | 2023-09-12 |
CL2023000468A1 (es) | 2023-08-04 |
IL300610A (en) | 2023-04-01 |
CA3189908A1 (en) | 2022-02-24 |
AU2021329805A1 (en) | 2023-03-09 |
DOP2023000036A (es) | 2023-04-16 |
US20220056017A1 (en) | 2022-02-24 |
US11680060B2 (en) | 2023-06-20 |
MX2023001840A (es) | 2023-03-13 |
ECSP23012026A (es) | 2023-03-31 |
CR20230089A (es) | 2023-04-11 |
CN116249697A (zh) | 2023-06-09 |
US20230365533A1 (en) | 2023-11-16 |
KR20230053639A (ko) | 2023-04-21 |
AU2021329805B2 (en) | 2024-02-29 |
BR112023002957A2 (pt) | 2023-04-04 |
JP7443625B2 (ja) | 2024-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2023001795A2 (es) | Agonistas de bicicloheptano pirrolidina de los receptores de orexina | |
EA202193338A1 (ru) | Терапевтические композиции, включающие дейтерированные или частично дейтерированные соединения n,n-диметилтриптамина | |
ECSP056097A (es) | Antagonistas del receptor cgrp | |
ECSP099374A (es) | Antagonistas de receptor de orexina de diazepan sustituido | |
ES2183937T3 (es) | Inhibidores de la adhesion celular. | |
ECSP055719A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
ECSP066879A (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos | |
UY30287A1 (es) | Dihidrotienopirimidinas para el tratamiento de enfermedades inflamatorias | |
AR013477A1 (es) | Prostaglandinas de tetrahidro sustituido c16-20 aromatico utiles como agonistas de fp. | |
MA54133B1 (fr) | Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y | |
GT200000203A (es) | Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas. | |
CO2023007838A2 (es) | Compuestos farmacéuticos | |
UY28317A1 (es) | Compuestos útiles para el tratamiento de enfermedades | |
CO2019007409A2 (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos | |
CR20220536A (es) | Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune | |
AR123273A1 (es) | Agonistas de bicicloheptano pirrolidina de los receptores de orexina | |
MX2023005073A (es) | Agonistas macrociclicos de los receptores de urea orexina. | |
AU2020288559A8 (en) | Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists | |
UY39681A (es) | Derivados de ciclobutilo 1,3–sustituidos y sus usos | |
WO2022129047A3 (en) | Modulators of the nmda receptor | |
ES2112832T3 (es) | Derivados carbamoilicos. | |
BR112022020012A2 (pt) | Composições que compreendem 15-hepe e métodos de tratamento ou prevenção de distúrbios hematológicos e/ou doenças relacionadas | |
AR123685A1 (es) | Antagonistas del mrgx2 | |
BRPI0406670A (pt) | Processo para a preparação de lactamas policìclicas fundidos com arila | |
CL2023002960A1 (es) | Composiciones y metodos para inhibir la expresion del miembro h del grupo h del grupo h 3 (nr1h3) del receptor nuclear |